Vertex Pharmaceuticals Inc (VRTX)
NASDAQ · Healthcare · Biotechnology
Vertex Pharmaceuticals Inc is a Healthcare company with a market capitalization of $123.94B and a trailing P/E ratio of 28.5.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 4, 2026 | $4.47 | $4.31 | +3.8% |
| Q4 2025 | February 12, 2026 | $5.03 | $5.15 | -2.3% |
| Q3 2025 | November 3, 2025 | $4.80 | $4.58 | +4.8% |
| Q2 2025 | August 4, 2025 | $4.52 | $4.25 | +6.3% |
| Q1 2025 | May 5, 2025 | $4.06 | $4.29 | -5.4% |
| Q4 2024 | February 10, 2025 | $3.98 | $4.02 | -1.0% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 4,986,691 | 1.95% | 3.1 | +1.0% |
| June 30, 2026 | 4,938,472 | 1.93% | 2.0 | +7.0% |
| June 15, 2026 | 4,616,968 | 1.80% | 3.8 | +2.8% |
| May 29, 2026 | 4,491,490 | 1.75% | 3.2 | +0.7% |
| May 15, 2026 | 4,461,773 | 1.74% | 3.6 | +6.9% |
| April 30, 2026 | 4,172,829 | 1.63% | 4.3 | -3.8% |
| April 15, 2026 | 4,336,502 | 1.69% | 3.8 | +7.8% |
| March 31, 2026 | 4,021,854 | 1.57% | 2.7 | -2.6% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Vertex Pharmaceuticals Inc's market cap?
As of August 13, 2026, Vertex Pharmaceuticals Inc (VRTX) has a market capitalization of $123.94B.
What is Vertex Pharmaceuticals Inc's P/E ratio?
Vertex Pharmaceuticals Inc trades at a trailing price-to-earnings (P/E) ratio of 28.5. Its forward P/E is 25.7.
Does Vertex Pharmaceuticals Inc pay a dividend?
Vertex Pharmaceuticals Inc does not currently pay a dividend.
What sector is VRTX in?
Vertex Pharmaceuticals Inc is in the Healthcare sector, specifically the Biotechnology industry.
What is Vertex Pharmaceuticals Inc's short interest?
As of the July 15, 2026 FINRA settlement, 4,986,691 VRTX shares were sold short, or 1.95% of shares outstanding. Days to cover: 3.1. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Vertex Pharmaceuticals Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Vertex Pharmaceuticals Inc reported revenue of $12.07B and net income of $3.95B.
Ask your own questions about VRTX
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.